- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02616601
Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis
June 24, 2019 updated by: Actavis Inc.
A Multicenter, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Comparison Study to Determine the Therapeutic Equivalence of Generic Fluorouracil Cream, 0.5% and Carac® (Fluorouracil) Cream, 0.5% in Subjects With Actinic Keratoses
This study is to evaluate the efficacy and safety of a generic formulation of fluorouracil 0.5% cream against the brand product (Carac) in participants with actinic keratoses.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This is a multicenter, double-blind, vehicle-controlled, parallel group comparison study of a generic fluorouracil cream, 0.5% and Carac (fluorouracil) Cream, 0.5% in participants with actinic keratoses on the full face or balding scalp.
Study Type
Interventional
Enrollment (Actual)
422
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Fremont, California, United States
- Investigative Site 2
-
Los Angeles, California, United States
- Investigative Site 16
-
San Diego, California, United States
- Investigative Site 17
-
-
Colorado
-
Denver, Colorado, United States
- Investigative Site 4
-
-
Georgia
-
Newnan, Georgia, United States
- Investigative Site 10
-
-
Idaho
-
Boise, Idaho, United States
- Investigative Site 5
-
-
Illinois
-
Arlington Heights, Illinois, United States
- Investigative Site 1
-
Buffalo Grove, Illinois, United States
- Investigative Site 11
-
-
Indiana
-
Carmel, Indiana, United States
- Investigative Site 3
-
Plainfield, Indiana, United States
- Investigative Site 9
-
South Bend, Indiana, United States
- Investigative Site 6
-
-
Michigan
-
Clinton Township, Michigan, United States
- Investigative Site 8
-
Warren, Michigan, United States
- Investigative Site 13
-
-
Minnesota
-
Fridley, Minnesota, United States
- Investigative Site 12
-
-
New Mexico
-
Albuquerque, New Mexico, United States
- Investigative Site 15
-
-
North Carolina
-
High Point, North Carolina, United States
- Investigative Site 7
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
- Investigative Site 14
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participant is male and/or female, 18 years of age or older.
- Participant is willing and able to give written informed consent.
- Participant is willing and able to apply the test article(s) as directed, comply with study instructions and commit to all follow-up visits for the duration of the study.
- Participant has a clinical diagnosis of actinic keratoses with at least 5 and no more than 10 clinically typical, visible or palpable, discrete, actinic keratoses (AK) lesions, each at least 4 millimeters (mm) in diameter on the face (excluding ears) or balding scalp.
- Participant is in good general health and free of any disease state or physical condition that might impair evaluation of AK lesions or which, in the investigator's opinion, exposes the participant to an unacceptable risk by study participation.
- Females must be post-menopausal, surgically sterile, or use an effective method of birth control with a negative urine pregnancy test (UPT) at the Baseline Visit.
Exclusion Criteria:
- Participant is pregnant, lactating, or is planning to become pregnant during the study.
- Participant is currently enrolled in an investigational drug or device study.
- Participant has used an investigational drug or investigational device treatment within 30 days prior to the Baseline Visit.
- Participant has hyperkeratotic, hypertrophic, or large mat-like AK lesions (for example, an AK lesion >1 cm^2 in size) within the treatment area.
- Participant has the need or plans to be exposed to artificial tanning devices or excessive sunlight during the study.
- Participant is immunosuppressed (for example, human immunodeficiency virus (HIV), systemic malignancy, graft host disease)
- Participant has experienced an unsuccessful outcome from previous topical fluorouracil therapy (an unsuccessful outcome is defined as after a reasonable therapeutic study with no compliance issues and the topical drug did not work).
- Participant has a history of sensitivity to any of the ingredients in the test articles.
- Participant has known dihydropyrimidine dehydrogenase (DPD) enzyme deficiency.
- Participant used topical creams, lotions, or gels of any kind within the selected treatment area within 1 day prior to entry into the study.
- Participant has used topical medications; corticosteroids, alpha hydroxy acids (for example, glycolic acid, lactic acid, etc. >5%), beta hydroxy acid (salicylic acid >2%), urea >5%, 5-fluorouracil, diclofenac, imiquimod, ingenol mebutate; or prescription retinoids (for example, tazarotene, adapalene, tretinoin) within the selected treatment area (face or balding scalp) within 1 month prior to the Baseline Visit.
- Participant has had cryodestruction, curettage, photodynamic therapy, surgical excision, or other treatments for AK within the selected treatment area (face or balding scalp) within 1 month prior to the Baseline Visit.
- Participant has used oral corticosteroid therapy, interferon, cytotoxic drugs, immunomodulators, immunosuppressive therapies, or retinoids within 1 month prior to the Baseline Visit.
- Participant has had dermatologic procedures or surgeries such as: laser resurfacing, Psoralen + ultraviolet A (PUVA) therapy, ultraviolet B therapy, chemical peels, or dermabrasion within the selected treatment area (face or balding scalp) within 6 months prior to the Baseline Visit.
- Participant has lesions suspicious for skin cancer (skin cancer not ruled out by biopsy) or untreated skin cancers within the selected treatment area (face or balding scalp).
- Participant has any skin pathology or condition on the face or balding scalp that, in the Investigator's opinion, could interfere with the evaluation of the test article or requires the use of interfering topical, systemic, or surgical therapy.
- Participant has any condition which, in the Investigator's opinion, would make it unsafe or preclude the participant's ability to fully participate in this research study.
- Participant is unable to communicate or cooperate with the Investigator due to language problems, poor mental development, impaired cerebral function, or physical limitations.
- Participant is known to be noncompliant or is unlikely to comply with the requirements of the study protocol (for example, due to alcoholism, drug dependency, mental incapacity) in the opinion of the Investigator.
- Participant has been previously enrolled in the same study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Generic Fluorouracil Cream
Participants are to apply up to 1 gram of generic fluorouracil 0.5% topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible.
Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime.
Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water.
Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
|
Topical cream, generic formulation of the brand product.
Other Names:
|
Active Comparator: Carac® (Fluorouracil) Cream
Participants are to apply up to 1 gram of Carac (fluorouracil) 0.5% topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible.
Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime.
Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water.
Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
|
Topical cream, brand product.
Other Names:
|
Placebo Comparator: Vehicle Cream
Participants are to apply up to 1 gram of vehicle topical cream once daily for 2 weeks as a thin film to the skin of the treatment area and rub until the cream is no longer visible.
Participants will be instructed to apply the study drug 10 minutes after thoroughly washing, rinsing, and drying the entire treatment area and 1 to 2 hours before bedtime.
Study drug should be left on the skin for approximately 8 hours and then removed by washing the area with mild soap and water.
Treatment should be continued for the full treatment course even if the actinic keratoses lesions appear to be gone.
|
Topical cream, placebo.
Has no active ingredient.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Treatment Success (Complete Clearance) at Week 6
Time Frame: Week 6
|
Percentage of participants with treatment success (complete clearance) at Week 6 (4 weeks after completion of 2 weeks of treatment).
Complete clearance was defined as having no (zero) clinically visible actinic keratoses (AK) lesions in the treatment area at the Week 6/End Of Study visit.
All AK lesions (baseline and new lesions) independent of size within the treatment area were treated and included in the efficacy lesion count.
|
Week 6
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Study Director, Actavis Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 27, 2015
Primary Completion (Actual)
September 17, 2015
Study Completion (Actual)
September 17, 2015
Study Registration Dates
First Submitted
November 25, 2015
First Submitted That Met QC Criteria
November 25, 2015
First Posted (Estimate)
November 30, 2015
Study Record Updates
Last Update Posted (Actual)
July 17, 2019
Last Update Submitted That Met QC Criteria
June 24, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 094-8251-301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Actinic Keratosis
-
Dolorgiet GmbH & Co. KGd.s.h. statistical services GmbH; CenTrial GmbHCompletedActinic Keratosis Olsen Grade I/IIGermany
-
Cosmetique Active InternationalNot yet recruiting
-
Centre Dermatologique du RoyCompleted
-
Encube Ethicals Pvt. Ltd.CBCC Global ResearchCompleted
-
University of California, DavisActive, not recruiting
-
Northwestern UniversityWithdrawn
-
Tulane UniversityMayne Pharma International Pty LtdTerminatedActinic KeratosesUnited States
-
Medical University of ViennaTerminatedActinic KeratosesAustria
-
University Hospital RegensburgGerman Research FoundationCompleted
-
St Vincent's University Hospital, IrelandCompleted
Clinical Trials on Generic Fluorouracil Cream
-
Spear PharmaceuticalsCompleted
-
Neal WeintraubUniversity of CincinnatiTerminated
-
Boston UniversityRecruitingSuperficial Basal Cell Carcinoma | Squamous Cell Carcinoma in SituUnited States
-
University of NebraskaTeva Branded Pharmaceutical Products R&D, Inc.WithdrawnMultiple SclerosisUnited States
-
Encube Ethicals Pvt. Ltd.CBCC Global ResearchCompleted
-
State University of New York - Downstate Medical...Active, not recruiting
-
Carilion ClinicRecruiting
-
Teva Pharmaceuticals USACompletedActinic KeratosisUnited States
-
SanofiCompletedActinic KeratosesUnited States
-
The Cleveland ClinicNational Cancer Institute (NCI)TerminatedActinic Keratosis | Organ or Tissue Transplant; ComplicationsUnited States